Interius

Interius company information, Employees & Contact Information

Updated May 2026

Quick answer

Interius is a Interior Design company and founded in 2018. It has approximately 61 employees on record. Contact data was last refreshed in May 2026. Find Interius's verified employee emails, phone numbers, headquarters address, and key decision makers below.

Explore related pages

Related company profiles:

Welcome to INTERIUS! We are a leading interior design firm, supported by the Skandhanshi Group. INTERIUS is known for its commitment to customer satisfaction, innovative designs, & exceptional post-sales service. The INTERIUS Experience Center is a hub for creating your dream space, offering thousands of quality-tested interiors, decor, and furniture elements. Our interior services in Hyderabad, Kurnool, Anantapur, Bengaluru, & Ballari provide a transformative journey to elevate your space into a realm of timeless elegance & style. With industry experts guiding you, you can create your ideal environment. INTERIUS is a center that offers a unique product exploration experience, allowing users to unleash their creativity & transform their spaces, redefining the art of interior design in the industry. INTERIUS merges your vision and expertise in interior design, ensuring transformative experiences by pushing boundaries & blending your vision with our expertise.

Company Details

Employees
61
Founded
-
Address
Skandhanshi Empire Building, Door, No: 50/727-Skn-3f, Beside Cn Hospital, Gooty Road,india
Industry
Interior Design
NAICS
Interior Design Services
HQ
Kurnool , Hyderabad , Bangalore, Andhra Pradesh
Looking for a particular Interius employee's phone or email?

Interius Questions

News

Gilead’s Kite scoops in vivo CAR-T specialist Interius for $350m - Pharmaceutical Technology

Gilead’s Kite scoops in vivo CAR-T specialist Interius for $350m Pharmaceutical Technology

Kite's Acquisition of Interius: A New Era for CAR-T in Philly - BioBuzz

Kite's Acquisition of Interius: A New Era for CAR-T in Philly BioBuzz

Gilead dives into ‘in vivo’ cell therapy with $350M buyout of Interius - BioPharma Dive

Gilead dives into ‘in vivo’ cell therapy with $350M buyout of Interius BioPharma Dive

Kite acquires Interius to develop in vivo cell therapies - BioProcess International

Kite acquires Interius to develop in vivo cell therapies BioProcess International

Gilead Subsidiary Kite to Acquire Interius BioTherapeutics for $350 Million - Pharmaceutical Executive

Gilead Subsidiary Kite to Acquire Interius BioTherapeutics for $350 Million Pharmaceutical Executive

Kite to buy Interius for $350 million - The Pharma Letter

Kite to buy Interius for $350 million The Pharma Letter

Penn biotech spin-out Interius acquired in $350 million deal - The Daily Pennsylvanian

Penn biotech spin-out Interius acquired in $350 million deal The Daily Pennsylvanian

Kite to Acquire Interius BioTherapeutics to Advance In Vivo Platform - Business Wire

Kite to Acquire Interius BioTherapeutics to Advance In Vivo Platform Business Wire

Gilead unit to acquire cell therapy developer Interius for $350 million - Reuters

Gilead unit to acquire cell therapy developer Interius for $350 million Reuters

Gilead to buy off-the-shelf CAR-T pioneer Interius for $350M - FirstWord Pharma

Gilead to buy off-the-shelf CAR-T pioneer Interius for $350M FirstWord Pharma

Gilead's Kite sails into in vivo CAR-T space with $350M Interius buyout - Fierce Biotech

Gilead's Kite sails into in vivo CAR-T space with $350M Interius buyout Fierce Biotech

Gilead buys in vivo cell therapy firm Interius for $350m - pharmaphorum

Gilead buys in vivo cell therapy firm Interius for $350m pharmaphorum

Gilead’s Kite to acquire Interius BioTherapeutics for $350 million - Investing.com

Gilead’s Kite to acquire Interius BioTherapeutics for $350 million Investing.com

California company to purchase Interius BioTherapeutics - Pennsylvania Business Report -

California company to purchase Interius BioTherapeutics Pennsylvania Business Report -

Gilead unit to acquire cell therapy developer Interius for $350 million - PharmaLive

Gilead unit to acquire cell therapy developer Interius for $350 million PharmaLive

Kite to Acquire Philadelphia-based Interius BioTherapeutics for In Vivo CAR T Therapy Platform - BioBuzz

Kite to Acquire Philadelphia-based Interius BioTherapeutics for In Vivo CAR T Therapy Platform BioBuzz

Gilead's (GILD) Kite Acquires Interius for $350 Million - GuruFocus

Gilead's (GILD) Kite Acquires Interius for $350 Million GuruFocus

Kite to Acquire Interius BioTherapeutics to Advance In Vivo Plat - GuruFocus

Kite to Acquire Interius BioTherapeutics to Advance In Vivo Plat GuruFocus

The Rise of the CAR-T Corridor: How Philadelphia and Maryland Are Shaping the Future of Cell Therapy - BioBuzz

The Rise of the CAR-T Corridor: How Philadelphia and Maryland Are Shaping the Future of Cell Therapy BioBuzz

Interius BioTherapeutics In Vivo CAR Therapy INT2104 Cleared for Phase 1 Clinical Trial in B-cell Malignancies Australia - CGTLive®

Interius BioTherapeutics In Vivo CAR Therapy INT2104 Cleared for Phase 1 Clinical Trial in B-cell Malignancies Australia CGTLive®

M&A analysis: Genmab bucks the bargain basement trend - Oncology Pipeline

M&A analysis: Genmab bucks the bargain basement trend Oncology Pipeline

Kite To Buy Interius BioTherapeutics In $350 Million Deal - Pulse 2.0

Kite To Buy Interius BioTherapeutics In $350 Million Deal Pulse 2.0

Interius BioTherapeutics Doses First Patient with in vivo - GlobeNewswire

Interius BioTherapeutics Doses First Patient with in vivo GlobeNewswire

Gilead's Kite erodes $2.3B off-the-shelf cell therapy deal with Shoreline - Fierce Biotech

Gilead's Kite erodes $2.3B off-the-shelf cell therapy deal with Shoreline Fierce Biotech

Gilead's Kite division snaps up Interius BioTherapeutics to advance cancer treatment technology - The Business Journals

Gilead's Kite division snaps up Interius BioTherapeutics to advance cancer treatment technology The Business Journals

Gilead’s Kite Is Latest To Enter In Vivo CAR-T Space With Interius Buy - Citeline News & Insights

Gilead’s Kite Is Latest To Enter In Vivo CAR-T Space With Interius Buy Citeline News & Insights

First Patient Dosed with In Vivo Gene Therapy for CAR T - Inside Precision Medicine

First Patient Dosed with In Vivo Gene Therapy for CAR T Inside Precision Medicine

The in vivo revolution: How Interius, Umoja, and Vyriad are transforming CAR-T cell therapy - Labiotech.eu

The in vivo revolution: How Interius, Umoja, and Vyriad are transforming CAR-T cell therapy Labiotech.eu

Gilead Sciences Surges 26.5% YTD: Buy, Sell or Hold the Stock? - TradingView

Gilead Sciences Surges 26.5% YTD: Buy, Sell or Hold the Stock? TradingView

Gildea's Kite Pharma Just Acquired Interius—$350 Million Move Shakes Up Cancer Therapy - Benzinga

Gildea's Kite Pharma Just Acquired Interius—$350 Million Move Shakes Up Cancer Therapy Benzinga

A faster, simpler, cheaper cancer cell therapy is about to be tested in humans - statnews.com

A faster, simpler, cheaper cancer cell therapy is about to be tested in humans statnews.com

Interius Gets Go-Ahead for Phase I Trial of In Vivo CAR-T Therapy in Australia - BioSpace

Interius Gets Go-Ahead for Phase I Trial of In Vivo CAR-T Therapy in Australia BioSpace

In vivo Car-T heads for the clinic, but it’s not Sana’s | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline

In vivo Car-T heads for the clinic, but it’s not Sana’s | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

In vivo CAR T cells move into clinical trials - Nature

In vivo CAR T cells move into clinical trials Nature

Lilly’s obesity drug looks more potent than Novo’s in observational study - statnews.com

Lilly’s obesity drug looks more potent than Novo’s in observational study statnews.com

10 Best Growth Stocks to Buy for the Next 2 Years - Insider Monkey

10 Best Growth Stocks to Buy for the Next 2 Years Insider Monkey

Ensoma and Interius BioTherapeutics: in vivo veritas - Nature

Ensoma and Interius BioTherapeutics: in vivo veritas Nature

Interius BioTherapeutics Announces Successful Manufacturing Partnership with WuXi Advanced Therapies - PR Newswire

Interius BioTherapeutics Announces Successful Manufacturing Partnership with WuXi Advanced Therapies PR Newswire

NextUp: The Philly Biotech Company Developing an In Vivo Approach to CAR T-Cell Therapy - Philadelphia Magazine

NextUp: The Philly Biotech Company Developing an In Vivo Approach to CAR T-Cell Therapy Philadelphia Magazine

Top Interius Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant